
A GWAS meta-analysis suggests roles for xenobiotic metabolism and ion channel activity in the biology of stool frequency

Stool consistency and frequency patterns are complex traits that are often altered in GI disease, and recent studies published in *Gut* highlight the importance of stool frequency in relation to gut microbiota composition and the efficacy of pharmacological and dietary treatments in IBS. ^{1–3}

Despite reported heritability invertebrates⁴ and similar evidence from open-field defaecation models in rats,⁵ the genetics of stool frequency has not been explored in humans. We undertook a genome-wide association study (GWAS) in two well-characterised population-based cohorts with genotype and defaecation data available: LifeLines-Deep (LLD) from the Netherlands (N=1546; 58% females; mean age 44 years (range 18-86)) and PopCol (PC) from Sweden (N=284; 60% females; mean age 54 years (range 22–71)).6 7 The average number of bowel movements per day (BM/d) was extracted from daily records kept by both populations and did not differ between cohorts (LLD=1.39 ± 0.64 SD; PC=1.42 ± 0.74 SD). Available CytoChip+Immunochip (LLD) HumanOmniExpressExome (PC) Illumina single-nucleotide polymorphism genotype data were imputed IMPUTE2 (https://mathgen.stats.ox.ac.uk/ impute/impute v2.html) with the Genome of the Netherlands (http://www.nlgenome. nl/) as reference. SNPs were filtered on minor allele frequency >0.05 and Hardy-Weinberg equilibrium p>1E-04, samples were filtered on infoscore >0.8 and population outliers were excluded using principal component analysis. In total, high-quality genotype data for 5 390 800 common SNPs and BM/d information were obtained for 1022 LLD and 259 PC individuals. Genotype-BM/d association tests were performed in SNPTEST (https://mathgen. stats.ox.ac.uk/genetics software/snptest/ snptest.html) using logistic regression under an additive model correcting for age and sex, followed by a fixed-effect model with META meta-analysis mathgen.stats.ox.ac.uk/genetics software/ meta/meta.html). Summary statistics for the top-10 loci from the meta-analysis and the corresponding effect of associated alleles on the frequency (increased/decreased) of defaecation are given in figure 1.

Although none of these associations achieved genome-wide significance

756 Gut April 2017 Vol 66 No 4



Meta-analysis LLD-PC, Age and gender corrected, MAF > 0.05

#	Lead SNP	Chr	BP	SNP	Assessed allele	P-value	Beta	se	Nearest gene	Other genes in 250kb region (protein coding)
1	rs62498365	8	17622887	C/T	Т	4.8E-07	-0.38	0.08	MTUS1	SLC7A2, PDGFRL, FGL1, PCM1
2	rs13959	9	75545882	G/A	A	7.5E-07	0.20	0.04	ALDH1A1	ANXA1, TMC1
3	rs735320	3	42915878	C/T	Т	7.7E-07	-0.27	0.05	CYP8B1	HHATL, NKTR, ZBTB47, CCDC13, HIGD1A, KLHL40, ZNF662, FAM198A, ACKR2, KRBOX1, POMGNT2
4	rs9550650	13	21035343	A/G	G	1.0E-06	-0.27	0.06	CRYL1	GJB6, IL17D, IFT88
5	rs9782914	1	241892235	T/C	С	1.2E-06	0.29	0.06	WDR64	FH, CHML, EXO1, KMO, OPN3
6	rs4090286	11	7644539	G/C	С	1.3E-06	0.30	0.06	PPFIBP2	CYB5R2, OR5P2, OR5P3, OLFML1, SYT9
7	rs115304436	2	178944137	G/A	A	1.3E-06	0.40	0.08	PDE11A	RBM45, OSBPL6
8	rs408709	6	4568772	C/T	Т	2.1E-06	0.24	0.05	CDYL	
9	rs2377852	1	31901133	C/T	Т	5.6E-06	-0.27	0.06	SERINC2	FABP3, AC114494.1, NKAIN1, SNRNP40, ZC- CHC17, TINAGL1, HCRTR1, PEF1, COL16A1
10	rs1979097	7	17582940	C/G	G	5.9E-06	0.19	0.04	AHR	SNX13

Figure 1 Manhattan plot of the results from the meta-analysis of LifeLines-Deep (LLD) and PopCol (PC) genome-wide association studies. Single-nucleotide polymorphisms (SNPs) which are sorted according to their genomic positions are displayed on the X-axis, and the negative logarithm of the association p value for each SNP after meta-analysis is displayed on the Y-axis; each dot represents a SNP with a certain p value. The top-10 loci are indicated by numbers. Per locus, the statistics of the lead SNPs are shown, including the positions in the genome, the nearest genes and the genes in a 250 kb window around the lead SNPs. The effect of the assessed allele at each locus is indicated by beta; negative betas mean negative effect on the average number of bowel movements per day (BM/d) (decreased number of stool passes) and positive betas mean positive effect on the average number of BM/d (increased number of stool passes). Beta, direction of association; BP, base pair position; Chr, chromosome; SE, SE of the beta.

(possibly due to limited sample size), we found excellent functional candidates mapping to these regions. For instance, the second strongest signal included the ALDH1A1 gene, which belongs to the family of aldehyde dehydrogenases, and member of this family (ALDH1AL1) has been shown to affect human gut microbiota composition.8 Moreover, Gene Network coexpression (http://www.genenetwork.nl/ analysis genenetwork/) indicated a role for ALDH1A1 in the cytochrome P450 metabolism of drugs and xenobiotics, and other genes in this pathway also map to top BM/d GWAS loci: the rs735320 signal comes from SNPs in the CYP8B1 gene, which belongs to the cytochrome P450

family; the rs4090 286 locus contains CYB5R2 (cytochrome B5 reductase), which is involved in cholesterol biosynthesis, fatty acid desaturation and elongation; and the rs1979097 locus contains AHR (ligand-activated aryl hydrocarbon receptor), which is a transcription factor modulating gene expression along the cytochrome P450 pathway. The genetic implication of xenobiotic and P450 metabolic pathways is not unexpected, given the interactions linking diet, gut microbiome and pharmaceutical compounds to known effects on human defaecation patterns, but was not reported previously.

A broader pathway analysis (http://129. 125.135.180:8080/GeneNetwork/pathway.

html), including genes from all 53 loci with p<5E-05, identified the *sodium channel complex* and *voltage-gated sodium channel activity* as the most enriched pathways in Gene Ontology (GO) terms for *cellular component* and *molecular function*, respectively (table 1). This is remarkable, since genetic defects in the voltage-gated channel *SCN5A* have been found in a subset of patients with IBS, and normal stool frequency was restored in a severely constipated *SCN5A* mutant carrier treated with mexiletine, a drug able to rescue *SCN5A* expression.⁹

In conclusion, we report the first GWAS of stool frequency in two harmonised population-based cohorts from the Netherlands and Sweden and highlight

Gut April 2017 Vol 66 No 4 757

Table 1 Pathway analysis of GWAS meta-analysis results for the average number of BM/d

Top associated GO term	p Value
Cellular component	
Sodium channel complex	6E-07
Sarcolemma	2E-05
Voltage-gated sodium channel complex	2E-05
Ion channel complex	6E-05
Molecular function	
Voltage-gated sodium channel activity	2E-05
Peptidase regulator activity	3E-05
Substrate-specific channel activity	4E-05
Ion channel activity	4E-05
Passive transmembrane transporter activity	7E-05
Channel activity	7E-05
Endopeptidase inhibitor activity	8E-05

Only GO pathways with p<1E-04 are reported. BM/d, bowel movements per day; GO, Gene Ontology; GWAS, genome-wide association study.

plausible candidate genes and biological pathways. Although we are not aware of similar datasets in which our findings may be replicated, the growing interest in this research area warrants larger studies to reach unequivocal conclusions.

Soesma A Jankipersadsing,^{1,2}
Fatemeh Hadizadeh,^{3,4} Marc Jan Bonder,²
Ettje F Tigchelaar,^{2,5} Patrick Deelen,^{2,6}
Jingyuan Fu,^{1,2} Anna Andreasson,^{7,8}
Lars Agreus,⁷ Susanna Walter,⁹ Cisca Wijmenga,²
Pirro Hysi,¹⁰ Mauro D'Amato,^{3,11}
Alexandra Zhernakova^{2,6}

¹Department of Pediatrics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

²Department of Genetics, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands

³Department of Biosciences and Nutrition, Karolinska Institutet, Stockholm, Sweden

⁴School of Nutrition, Isfahan University of Medical Sciences, Isfahan, Iran

⁵Top Institute Food and Nutrition, Wageningen, The Netherlands

⁶University of Groningen, University Medical Center Groningen, Genomics Coordination Center, Groningen, The Netherlands ⁷Division of Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

⁸Stress Research Institute, Stockholm University, Stockholm, Sweden

⁹Division of Gastroenterology, Institution of Clinical and Experimental Medicine, Linköping University, Linköping, Sweden

¹⁰Department of Ophthalmology, King's College London, St Thomas' Hospital Campus, London, UK ¹¹BioDonostia Health Research Institute San Sebastian and IKERBASQUE, Basque Foundation for Science, Bilbao, Spain

Correspondence to Dr Alexandra Zhernakova, Department of Genetics CB50, UMCG, PO Box 30001, Groningen 9700 RB, The Netherlands; a.zhernakova@ umcq.nl

SAJ and FH shared first author. MD'A and AZ shared last author.

Acknowledgements The authors thank Jackie Senior for editing the text.

Contributors AZ, MD'A and CW designed the study. AZ, EFT, JF, AA, LA, SW and CW initiated the cohort and collected cohort data. SAJ, AA, LA, SW and EFT generated data. FH, MJB, PD, SAJ, JF and PH analysed data. MD'A, AZ, SAJ, PH and CW wrote the manuscript.

Funding This work was funded by grants from the Top Institute Food and Nutrition, Wageningen, to CW (GH001), the Netherlands Organization for Scientific Research to JF (NWO-VIDI 864.13.013) and the Swedish Research Council (VR) to MD'A. AZ holds a Rosalind Franklin fellowship (University of Groningen).

Competing interests None declared.

Patient consent Obtained.

Ethics approval The LifeLines-DEEP study was approved by the ethics committee of the University Medical Center Groningen, the Netherlands (document no. METC UMCG LLDEEP: M12.113965). The PopCol study was approved by Karolinska Institutet's ethics committee, Stockholm, Sweden (dnr 394/01). All participants signed an informed consent form prior to study enrolment.

Provenance and peer review Not commissioned; internally peer reviewed.



Open Access This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build

upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/



To cite Jankipersadsing SA, Hadizadeh F, Bonder MJ, et al. Gut 2017;**66**:756–758.

Received 7 June 2016 Revised 20 June 2016 Accepted 4 July 2016 Published Online First 29 July 2016

Gut 2017;**66**:756–758. doi:10.1136/gutjnl-2016-312398

REFERENCES

- Hadizadeh F, Walter S, Belheouane M, et al. Stool frequency is associated with gut microbiota composition. Gut 2017;66:559–60.
- 2 Tack J, Schumacher K, Tonini G, et al. The neurokinin-2 receptor antagonist ibodutant improves overall symptoms, abdominal pain and stool pattern in female patients in a phase II study of diarrhoea-predominant IBS. Gut Published Online First: 15 Apr 2016. doi:10.1136/gutjnl-2015-310683
- McIntosh K, Reed DE, Schneider T, et al. FODMAPs alter symptoms and the metabolome of patients with IBS: a randomized controlled trial. Gut Published Online First: 14 Mar 2016. doi:10. 1136/gutjnl-2015-311339
- 4 Branicky R, Hekimi S. What keeps C. elegans regular: the genetics of defecation. *Trends Genet* 2006;22:571–9.
- 5 Blizard DA, Adams N. The Maudsley reactive and nonreactive strains: a new perspective. *Behav Genet* 2002:32:277–99
- 6 Tigchelaar EF, Zhernakova A, Dekens JAM, et al. Cohort profile: LifeLines DEEP, a prospective, general population cohort study in the northern Netherlands: study design and baseline characteristics. BMJ Open 2015:5:e006772.
- Walter SA, Kjellström L, Nyhlin H, et al. Assessment of normal bowel habits in the general adult population: the Popcol study. Scand J Gastroenterol 2010;45:556–66.
- 8 Goodrich JK, Davenport ER, Beaumont M, et al. Genetic determinants of the Gut Microbiome in UK Twins. Cell Host Microbe 2016;19:731–43.
- 9 Beyder A, Mazzone A, Strege PR, et al. Loss-offunction of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome. Gastroenterology 2014;146:1659–68.

758 Gut April 2017 Vol 66 No 4